What is LOPJLB’s current signal on ADAP?

LOPJLB’s latest quantitative signal on Adaptimmune Therapeutics plc (ADAP) is SELL in a CRISIS regime. Signals are updated daily.

What market regime is ADAP in?

Adaptimmune Therapeutics plc (ADAP) is currently classified in the CRISIS HMM market regime on LOPJLB.

Adaptimmune Therapeutics plc (ADAP)

COMPARE

Healthcare · Biotechnology · NASDAQ · GB

$0.05+0.00%Close

SELLCRISIS · day 7

RANGE

DATA 2025-10-28

LOPJLB.COM

OHLCEMALEVELSSTOPFLIP52WSIGNALSBUYSELLEXHEXH ZONEBEST

Key stats

Market cap: $13M
Beta: 2.49

P/E (TTM): -0.17

1W: +0.00%

vs SPY 1W: -1.16%

Industry peers

FMP comparable companies · ranked by market cap

ANLSELLAdlai Nortye Ltd.$829MCRISISQ 15$15.62-8.96%

Prediction markets

Kalshi · Polymarket · … linked

Full prediction markets →

Loading markets…

Company

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company dedicated to developing innovative cell therapies. Its primary focus is on addressing solid tumors in patients across the United States and the United Kingdom. At the core of its approach is the specific…

Employees: 506
Headquarters: GB
Founded: 2015
Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares out: 258.3M
Float: 98.9%

adaptimmune.com ↗

Key executives

Adrian G. Rawcliffe — Chief Executive Officer & Director

William C. Bertrand Jr. — Chief Operating Officer & Chief Compliance Officer

Helen Katrina Tayton-Martin — Co-Founder

SEC filings

EDGAR · CIK 16212270 · ADAP

Analyst consensus

Buy

Bullish956.3%

Neutral425.0%

Bearish318.8%

L $1.00Avg $2.83H $4.00

Target$2.83+5560.00%

Last$0.05

FAQ

What is LOPJLB’s current signal on ADAP?: LOPJLB’s latest quantitative signal on Adaptimmune Therapeutics plc (ADAP) is SELL in a CRISIS regime. Signals are updated daily.
What market regime is ADAP in?: Adaptimmune Therapeutics plc (ADAP) is currently classified in the CRISIS HMM market regime on LOPJLB.
What does Adaptimmune Therapeutics plc (ADAP) do?: Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company dedicated to developing innovative cell therapies. Its primary focus is on addressing solid tumors in patients across the United States and the United Kingdom. At the core of its approach is the specific peptide enhanced affinity receptor (SPEAR) T-cell platform, designed to precisely identify cancer targets. The company…

Key stats

Industry peers

Prediction markets

Company news

FAQ